Drug updated on 9/5/2024
| Dosage Form | Injection (intravenous: 50 to 5000 MBq/mL [1.4 to135 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
Latest News
Summary
- Neuraceq (florbetaben F 18) is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.
- This summary is based on the review of one systematic review(s)/meta-analysis(es). 3. [11C]PIB and Na[18F]F were effective in distinguishing ATTR-CM (cardiac amyloidosis) from cardiac light chain amyloidosis, while [18F]FBP was not effective in this differentiation. [1]
- Contradictory evidence was reported for the effectiveness of [18F]FBB and [18F]FMM in diagnosing cardiac amyloidosis across the reviewed studies.
- No studies were identified that assessed the effectiveness of PET tracers in the follow-up of ATTR amyloidosis patients.
- There is no safety information available in the reviewed studies regarding florbetaben f 18 or other PET tracers used.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Neuraceq (florbetaben F 18) prescribing information. | 2023 | Life Molecular Imaging Ltd., Warwick, United Kingdom |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review. | 2023 | European Journal of Nuclear Medicine and Molecular Imaging |